香港股市 已收市

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
4.0600-0.3400 (-7.73%)
收市價: 04:00PM EDT
4.1000 +0.04 (+0.99%)
收市後: 06:03PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價4.4000
開市4.3500
買盤4.0500 x 1400
賣出價4.1000 x 800
今日波幅3.9900 - 4.3900
52 週波幅2.1300 - 28.0900
成交量453,773
平均成交量1,355,582
市值249.523M
Beta 值 (5 年,每月)2.06
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-3.5640
業績公佈日2022年10月31日 - 2022年11月04日
遠期股息及收益率無 (無)
除息日
1 年預測目標價13.17
  • Benzinga

    MacroGenics Jumps Biotech Layoff Bandwagon, Cuts 15% Of Workforce

    MacroGenics Inc (NASDAQ: MGNX) announced a corporate restructuring involving a 15% workforce reduction, closure of an R&D facility, and closure of a manufacturing site. After discontinuing a Phase 2 study for enoblituzumab, a program that was upside to estimates, the company's pipeline efforts are more narrowly focused on MGC018, lorigerlimab, and MGD024. The Phase 2/3 study for MGC018 in metastatic castration-resistant prostate cancer (mCRPC) remains expected to initiate by YE22, and enrollment

  • Benzinga

    Analysts Cuts Price Target On MacroGenics - Read Why

    BMO Capital Markets downgraded MacroGenics Inc (NASDAQ: MGNX) to Market Perform following the discontinuation of enoblituzumab (B7H3 antibody) for head and neck cancers. The analyst said that enoblituzumab was not a meaningful contributor to the last valuation. The update has eroded confidence in MacroGenics's ability to address the unresolved safety issues with MCG018 (B7H3 ADC). The company's platform has delivered several clinically active molecules and one commercial program in Margenza. Rel

  • Benzinga

    Patient Death Prompts MacroGenics To Close Mid-Stage Head & Cancer Study

    MacroGenics Inc (NASDAQ: MGNX) closed the Phase 2 study (CP-MGA271-06) of enoblituzumab in the first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The trial evaluated the regimen of enoblituzumab in combination with either retifanlimab or tebotelimab. The decision to discontinue the study was based on an internal review of safety data, which included seven fatalities potentially associated with hemorrhagic events in both arms of the